• Influenza Hemagglutinin (HA) Peptide: Precision Tag for Adva

  2026-06-03

  The Influenza Hemagglutinin (HA) Peptide empowers precise detection and purification of HA-tagged proteins, setting a new standard for reproducibility in molecular workflows. Its competitive binding and high solubility streamline immunoprecipitation, while robust purity assures reliable data for complex cell biology and translational research.

• Dabigatran Etexilate: A Paradigm Shift in Oral Anticoagulati

  2026-06-03

  The reference paper reviews the clinical and pharmacological advances of dabigatran etexilate, the first oral direct thrombin inhibitor approved for stroke and VTE prevention. Its rapid, predictable action and independence from cytochrome P450 metabolism address major limitations of traditional anticoagulants and inform safer drug-drug interaction research.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-06-02

  Schwartz's dissertation introduces an advanced in vitro framework for distinguishing between cancer drug-induced cell death and proliferative arrest, challenging the common reliance on composite viability metrics. These methodological refinements improve the interpretive power of preclinical drug screening and have broad implications for kinase inhibitor research.

• Precision Protease Inhibition: Advancing Translational Prote

  2026-06-02

  This article explores how mechanistic understanding of protease activity—and the strategic selection of broad-spectrum, EDTA-free protease inhibitor cocktails—empowers translational researchers to preserve protein integrity in high-stakes applications. Drawing on recent advances in ferroptosis research and in-depth benchmarking of APExBIO’s Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO), we bridge molecular insight and practical guidance to chart a path toward reproducible, actionable protein science.

• (1S,3R)-RSL3: Precision GPX4 Inhibition and Ferroptosis in A

  2026-06-01

  Explore how (1S,3R)-RSL3, a targeted glutathione peroxidase 4 inhibitor, enables advanced ferroptosis research in both aging and oncogenic RAS-driven cancer models. This article reveals new mechanistic insights and assay decision points not covered elsewhere.

• Oltipraz: A 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thio

  2026-06-01

  Oltipraz is a verified Nrf2 pathway activator and potent glutathione S-transferase inducer. Its molecular activity includes upregulation of phase II detoxifying enzymes, supporting chemoprevention and xenobiotic defense. APExBIO offers high-purity Oltipraz for research, with standardized solubility and storage parameters.

• NFE2L1–UPS Activation by DDI2 Protects Cells from RSL3-Induc

  2026-05-31

  This study reveals how the DDI2-mediated activation of NFE2L1 and the ubiquitin-proteasome system (UPS) counteracts ferroptosis triggered by direct GPX4 inhibition with RSL3. The findings highlight a previously underappreciated feedback mechanism linking protein homeostasis to ferroptosis resistance, with potential implications for sensitizing cancer cells to ferroptosis-based therapies.

• Rosiglitazone (Brl-49653) in PPARγ-Driven Metabolic Research

  2026-05-30

  Rosiglitazone (Brl-49653) from APExBIO empowers researchers to dissect PPARγ pathways in adipogenesis, insulin sensitivity, and rare metabolic syndromes. This article interlinks advanced protocols, troubleshooting, and the latest reference breakthroughs to deliver reproducibility and translational insight.

• Carfilzomib (PR-171): Proteasome Inhibition in Oncology Work

  2026-05-29

  Carfilzomib (PR-171) stands out for its robust, irreversible proteasome inhibition, enabling multi-modal apoptosis induction in cancer research. This article details experimental protocols, troubleshooting insights, and cross-study innovations to help researchers optimize their use of Carfilzomib in translational oncology.

• RBMS1 Loss Enhances PD-L1 Blockade Response in TNBC

  2026-05-29

  This study uncovers RBMS1 as a key regulator of PD-L1 stability in triple-negative breast cancer (TNBC), demonstrating that RBMS1 loss sensitizes tumors to immune checkpoint therapies by promoting PD-L1 degradation. The findings highlight a novel mechanistic axis and offer new avenues for improving immunotherapy response in immune-cold TNBC.

• Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301): T

  2026-05-28

  Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) facilitate efficient capture, purification, and isolation of biotinylated molecules from complex samples, reducing background binding in workflows such as immunoprecipitation and protein interaction studies. This product should be reserved for applications that leverage the biotin-streptavidin interaction on hydrophobic bead surfaces, and is not suitable for workflows outside affinity capture or where hydrophobicity may interfere with results.

• IGF2BP3 Depletion Triggers Ferroptosis in Glioma via GPX4 Mo

  2026-05-28

  This study reveals that the m6A reader protein IGF2BP3 directly regulates GPX4 expression in glioma, and its depletion induces ferroptosis by destabilizing GPX4 mRNA at a specific m6A site. These findings clarify a novel post-transcriptional mechanism controlling ferroptosis and underscore the therapeutic potential of targeting IGF2BP3–GPX4 interactions in glioma.

• In Vitro Efficacy of Temafloxacin Versus Quinolones Against

  2026-05-27

  This literature review examines the in vitro potency of temafloxacin, a fluoroquinolone, against a spectrum of gram-negative bacteria, benchmarking its minimal inhibitory concentrations (MICs) versus established quinolone antibiotics such as cinoxacin. The findings clarify temafloxacin’s comparative advantages and inform experimental antibiotic selection in urinary tract and antibiotic resistance research.

• 25-Hydroxycholesterol Drives Immunosuppressive Macrophage Me

  2026-05-27

  Xiao et al. (2024) uncover a lysosomal 25-hydroxycholesterol (25HC)–AMPK–STAT6 axis that metabolically reprograms tumor-associated macrophages (TAMs) toward an immunosuppressive state. The study identifies CH25H as an immunometabolic checkpoint, suggesting new targets for modulating the tumor microenvironment and enhancing immunotherapy efficacy.

• TiO2-Nanoparticle Sonodynamic Therapy Induces Ferroptosis to

  2026-05-26

  The referenced study demonstrates that titanium dioxide nanoparticle-enhanced sonodynamic therapy (SDT) can effectively prevent posterior capsule opacification after cataract surgery by inducing ferroptosis in human lens epithelial cells. This mechanism, characterized by ROS accumulation and GPX4 downregulation, offers a targeted, biosafe approach that addresses a persistent complication in ophthalmology.

16703 records 1/1114 page Next 12345 下5页 Last page